Atopic dermatitis (AD) is one of the most common
skin diseases with
inflammation, chronic relapses, and intense
pruritus. Its pathogenesis includes
genetic susceptibility, an abnormal epidermal
lipid barrier, and an increased production of
IgE due to immune dysregulation. Recently, AD has been reported to be associated with intestinal
inflammation and
dysbiosis in human and murine models. Various probiotics are being used to control intestinal
dysbiosis and inflammatory reactions. However, it is difficult to predict or determine the
therapeutic effects of the probiotics, since it is rare for clinicians to use the probiotics alone to treat AD. It is also difficult to check whether the intestinal
inflammation in patients with AD has improved since probiotic treatment. The aim of the present study was to determine whether mice with induced
atopic dermatitis had any changes in fecal
calprotectin, an
indicator of intestinal
inflammation, after probiotic administration. Our results showed that the fecal
calprotectin levels in mice with induced
dermatitis decreased significantly after the administration of probiotics. In addition, epidermal skin lesions were attenuated and inflammatory-related
cytokines were downregulated after the administration of probiotics in mice with induced
dermatitis. These results suggest that changes in fecal
calprotectin levels could be used to assess the effectiveness of a probiotic strain as an adjuvant treatment for AD.